Last reviewed · How we verify

Formosa Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Formosa Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
APP13007, 0.05% APP13007, 0.05% phase 3 Prostaglandin F receptor agonist FP receptor (prostaglandin F receptor) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allergan · 2 shared drug classes
  2. Pfizer · 2 shared drug classes
  3. Medical University of Vienna · 2 shared drug classes
  4. AJU Pharm Co., Ltd. · 1 shared drug class
  5. AceLink Therapeutics, Inc. · 1 shared drug class
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. Abbott · 1 shared drug class
  8. Aciex Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Formosa Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Formosa Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/formosa-pharmaceuticals-inc. Accessed 2026-05-17.

Related